

Global Structured Credit Strategy

Value in AAA and Euro BBB

- **US AAAs continue to look cheap** — For all the robust credit performance and strength of CLO triple-As, the assets continue to trade cheap to its structured and corporate peers; we recommend more funds and banks look at them.
- **More bank involvement in senior bonds** — Our analysis shows banks are getting increasingly involved in CLO senior bonds for higher return on capital, and as an investment opportunity for the amount of liquidity that QE3 is likely to generate.
- **Seasoned bonds are rapidly amortizing** — A shorter duration and possible capital gains for discount bonds makes us recommend the CLO 1.0 triple-As. Loan repayment rates are running much higher than many investors' assumptions
- **Euro triple-Bs attractive despite new loss data** — European speculative-grade default rates are climbing but recoveries have surprised to the upside. At forecast default and recovery rates, Euro CLO mezz is tempting as a recovery play.
- **Buy Euro triple-Bs with turbo-BBs into cheapness** — Some investors prefer triple-Bs in deals without turbo-BBs for fear that turbos release cash early; our analysis of a mezz portfolio shows that the relative underperformance is marginal.
- **Issuance crosses \$30 billion** — With the entry of more CLO buyers, issuance is now well past double all of 2011 issuance. We note, September had the highest monthly volume and the last quarter the busiest one since the financial crisis.
- **Spreads tighten but still cheap to 2011** — Spreads have rallied across the board with triple-As lagging the rally somewhat and greater convergence between CLO 1.0 and CLO 2.0.

Ratul Roy

+1-212-723-6043
ratul.roy@citi.com

Anindya Basu

+1-212-723-6453
anindya.basu@citi.com

Daniel Choi

+1-212-723-6089
daniel.choi@citi.com

See Appendix A-1 for Analyst Certification, Important Disclosures and non-US research analyst disclosures.


Citi Research is a division of Citigroup Global Markets Inc. (the "Firm"), which does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.

Contents

CLO Market Snapshot – Volume and Spreads	3
Issuance more than double all of 2011	3
Debt spreads help in US and Europe	3
Profit-takers boost secondary supply	3
Buy CLO Triple-As	5
Triple-As are cheap to peer assets	5
CLO senior tranches have not defaulted	5
Reinstated ratings reverse overreaction	5
CLO Triple-As – Old or New?	6
Higher coupon, but new has a lot more	6
Older (CLO 1.0) deals can be shorter	6
Spreads have converged	6
Bank Involvement will Continue	7
CLO triple-As make sense for banks	7
QE3 has increased US banks' need for yield	7
High return on bank capital	7
Euro CLO Mezz – Much to Hope	8
Defaults rising, but...	8
...recoveries surprise positively	8
Do Turbos Matter for Euro BBBs?	9
Relative value despite rally	9
Turbo good for double-B, not bad for triple-B	9
Appendix	10
Appendix A-1	14

CLO Market Snapshot – Volume and Spreads

Figure 1. US CLO Issuance, \$bn



Source: Citi Research


Issuance more than double all of 2011

With the entry of more buyers into the CLO markets (see our 'Bank Involvement will Continue' section), CLO issuance is now well past double all of 2011 issuance. In fact, September had the highest monthly volume and the last quarter the busiest quarter (Figure 1) since the financial crisis in 2008. Our thesis that a relative lack of loan supply and tighter loan spreads would be bad for CLO supply has not proven right. New issue spreads have tightened helping projected equity returns, highlighting the well-known lag between underlying and CLO spreads. Several managers such as Prudential, CSAM, LCM, ING and Och-Ziff have already done more than one deal (a handful did three) this year, and we have also seen a few small, new managers such as Valcour and KVK benefit from the strong demand for the CLO product. Total issuance, including some middle-market deals, will exceed \$35bn for the year.

Debt spreads help in US and Europe


Though new issue spreads have tightened, there should be room to tighten further. Many investors are still apprehensive about mark-to-market leverage after the financial crisis, and the structural leverage of mezz and junior notes within a CLO structure has proven to be very attractive. What has lagged the rally in liability spreads are the triple-As (Figure 2) which is why we think there is relative value in this part of the capital structure (see the next section). Down the capital stack, mezzanine bonds bought at discount (see the last [Global Structured Credit Strategy](#)) offer an attractive combination of carry and convexity – that is, upside if deals are called plus reduced losses because of low-dollar purchase prices. And while Europe is nowhere close to a primary deal in the weeks ahead, the secondary market there has seen a substantial rally. The prospects for a European deal in the next few months are looking all the more likely as a result. Discount spreads for triple-As in the Euro CLO secondary market from deals that are still reinvesting (and thus akin to a hypothetical new issue deal with a short reinvestment period) are already in the high 100s area. This is not to say that a new deal will be straightforward – among other things, assembling a diversified collateral pool can still create challenges.

Figure 2. US CLO new issue spreads, bps



Source: Citi Research

Figure 3. CLO BWICs, \$million



Source: Citi Research

Profit-takers boost secondary supply


After a quiet few months, September looks like a bigger month for secondary bonds (Figure 3). In reality, though, much of the supply came in the form of triple-As and the level of secondary mezz supply has not increased. Demand is strong, but many legacy holders are reluctant to book losses despite higher prices. In contrast to mezz, the triple-A secondary supply is helped by having values close to par, which is close to where many legacy owners are holding assets. Banks are also better holders of CLO 2.0 assets versus CLO 1.0 for regulatory capital reasons, something which may be prompting some flow. Money-market funds may be incentivized to take up the supply especially if they are shorter-dated seasoned paper. Moreover, the Street has also been short inventory and dealers may be looking to build up their books. Some funds are also looking to take profits and sell into the rally. This

has been most visible in the amount of CLO equity in bid-lists since August and the attractive levels of bids.

Buy CLO Triple-As

Triple-As are cheap to peer assets

Figure 4. Peer high-quality triple-A structured asset spreads, bps




Source: Citi Research

Figure 5. CLOs that defaulted, with reason for default

Impairment Type	No of CLOs	No of Impaired Tranches	Highest Initial Rating of Impaired Tranche
Realized principal losses at maturity	14	32	Baa2
Distressed exchange	4	7	A2
EoD because of a market value feature	1	1	Ba2
Other tranches likely to suffer principal losses	12	19	A2
Total	31	59	A2

Source: Moody's

Figure 6. Distribution of original AAA-rated tranches versus time



Source: Citi Research, Moody's

For all the robust performance that CLO triple-As have evidenced over the last few years, CLO triple-As continue to trade cheap to its peers as we see in Figure 4. Most risky assets have benefited from the global liquidity injected by Central Banks, whether it is the Fed's latest version of quantitative easing, or ECB injections such as LTRO (or more recently confidence boosts such as Draghi's pledge to "do whatever it takes to save the euro"). In many bank treasurers' minds, the sector is still tarnished with the fall out from sub-prime mortgage-backed CDOs. The CLO market was also affected by its own idiosyncratic issues in the form of JPMorgan losses in its CIO office and the unwinding of previously-held positions (or halting of new purchases). At the same time, more regulatory focus on banks is dampening bank treasury demand. Finally, the absence of CLOs in many traditional fixed income indices also leaves out many investors, and may help to explain the outperformance of the CMBS asset class. Several banks, too, may have been using the mortgage-backed securities market to make up for a shortfall in real estate loans; this has helped CMBS rather than CLOs. There is evidence, however, that more banks are looking at credit, and this should help the CLO market in 2013.

CLO senior tranches have not defaulted

As new investors start considering the prospect of investing in triple-As it is worth reminding ourselves that triple-A CLOs have never defaulted¹. As we describe in Global Structured Credit Strategy, the 14 deals which did have principal losses (Figure 5) closed between 1997 and 2001. Most had invested heavily in high-yield bonds whose value deteriorated significantly in the stressful credit environment between 1999 and 2002. These first-generation deals preceded the vast CLO 1.0 universe of CLOs done between 2004 and 2007 and allowed maximum high yield bond exposure (low recoveries on which led to unexpectedly high losses to typically 25% of the asset pool). Other defaults were mostly technical in nature, or occurred because of problems in documentation (for example, one had an unintended market-value feature in the calculation of its OC-based EOD trigger which had an adverse impact after the temporary loan price fall after the financial crisis). Finally most of the deals which have a high likelihood of ultimate principal loss (according to Moody's) also have substantial HY bind buckets similar to the 14 that did default.

Reinstated ratings reverse overreaction

As seasoned CLO investors are all too aware, the last three years has seen a see-saw behavior from agencies. Most triple-A bonds saw downgrades after the financial crisis (Figure 6). Moody's for example added a 30% default probability stress in its rating model. The stress was a response to the disruption to the capital markets following the collapse of Lehman Brothers and the unpredictability of market conditions. Last year they felt that the stable credit conditions and low default rates for corporate credits warranted a removal of that new stress factor, which, combined with older CLOs starting to delever naturally as they exited their reinvestment period, led to many upgrades. Today, 99.4% of original Moody's rated Aaa tranches are rated above A1². Moreover, new vintage CLOs are expected to be more robust due to increased subordination (35% new vintage versus 25% for older vintages) that includes a new required cushion against future downgrade risk.


¹ Losses in US Cash Flow Tranches are Infrequent, CLOInterest, Moody's, 25 July 2012

² Structured Finance Rating Transitions: 1983-2011, Moody's, 23 March 2012

CLO Triple-As – Old or New?

Higher coupon, but new has a lot more

Figure 7. CLO 1.0 versus CLO 2.0; also shown coupons and prices (within brackets)




Source: Citi Research

A lot of recent debate has been about the value of CLO 2.0 versus CLO 1.0 (Figure 7). A major source of change is an increase in subordination. For example, Moody's recalibrated the default probability and recovery rate assumptions in its model in order to reduce the likelihood of future rating volatility resulting from assumption changes. So even though they removed the 30% stress (see previous page) the other changes to the model generally increased enhancement levels above pre-crisis levels. Other than higher subordination, debt tranches are also paying higher coupons relative to pre-2008 deals. The portfolio is cleaner too - currently 90-95% of a typical CLO 2.0 portfolio consists of senior secured loans, compared to 85-90% in the older version. No structured securities (typically other CLOs) may be included, unlike in CLO 1.0s. Moreover, tighter documentation regarding reinvestment in longer-dated collateral, allowing extensions of existing loans, and length of reinvestment period should all result in shorter and more certain average lives of senior tranches.

Older (CLO 1.0) deals can be shorter


Figure 8. US quarterly loan repayment rate



Source: S&P LCD

A shorter investment horizon and an opportunity for capital gains for secondary CLO 1.0 triple-As bought at high 90s price makes us recommend the older deals. Triple-A buyers will often price deals assuming a 10-20% prepayment rate. Figure 8 shows, however, that the repayment rate is running between 25 and 30%. Moreover loans are subject to repricing risk and current loan technicals such as new CLO creation and mutual fund flows are likely to keep the repayment rates high for a while. As a result triple-As are rapidly amortizing (Figure 9). More deals are likely to get called too. History (see [Global Structured Credit Strategy](#)) shows that there are two reasons for getting called. For older vintages (such as the 2001-2004 deals) the reason is that the average liability costs increase as triple-As pay down at the end of the reinvestment period (and will equal the liability costs of a new deal at some point), and, simultaneously, the leverage for equity declines. Moreover, with higher loan prices, the NAV of the portfolio may result in a higher immediate payout than the present value of these future cashflows. Both of these factors should result in more refinancings. Newer deals (from 2008 and 2009) are also refinancing candidates if triple-A spreads tighten a little. With the tightening, these deals will be able to reduce their liability costs by rolling into a new transaction.

Figure 9. Triple-A bond factor, by vintage, versus quarters after end of reinv period




Source: Citi Research

Spreads have converged

As a result of the shorter average lives and potential for capital gains in the event of a deal call, senior spreads have converged between CLO 1.0 and CLO 2.0. In some cases, the older deals have traded through new issue. A year ago, CLO 1.0 traded 60-75bps wide to CLO 2.0. The convergence between the two versions is made all the more remarkable given that CLO 2.0 is more suitable for banks (the floating rate nature of CLOs make them an ideal bank product, see next section) as they are not considered resecuritizations and attract lower regulatory capital. However money-market funds that have no such regulatory disincentive may prefer the CLO 1.0 shorter duration, despite the advantages offered by the newer version that we have highlighted above.

Bank Involvement will Continue CLO triple-As make sense for banks


Figure 10. Purchases of CLO 2.0 triple-As by investor segment



Source: Citi Research based on internal deals

Banks are getting increasingly involved in CLO senior bonds (Figure 10) – this time for the right reasons. Investors will recall many of the legacy banks bought CLO 1.0 senior tranches in leveraged vehicles such as ABCP conduits or SIVs. The vehicles ran into a liquidity crisis as they were not able to roll their shorter-dated CP liabilities that funded these longer-dated assets. Eventually the senior bonds (CLOs were only a small part of the portfolio which typically consisted of financials and a broader range of structured finance assets) were brought on the vehicle sponsors' balance-sheets. In the current market, banks are funding the assets internally. The reasons for investment are relative value, protection from credit losses, and the floating-rate nature of the bonds being apposite for the way banks fund themselves. Not only has the volume invested grown reflecting the higher size of the primary market, the number of investors has also increased (Figure 11). It also so happens that senior CLO tranches, especially of CLO 2.0 bonds, give a very high return on capital.

Figure 11. Number of new investors



Source: Citi Research based on internal deals

QE3 has increased US banks' need for yield

QE1 and QE2 has already led to excess bank reserves left at the Fed to increase, and resulted in tightening in yield for higher quality collateral such as treasury and Agency debentures and MBS. QE3 is likely to do more of the same. Even though banks are reporting a better lending environment, the odds are that most of the excess liquidity will end up being invested into more securities. With traditional MBS product already getting pretty rich, there's a good likelihood banks will be looking for higher coupon alternatives with relative value. Senior CLO bonds could fit the bill.

Figure 12. Illustrative return on capital (ROC) under Basel III and US (SSFA) interpretation

	CLO 2.0	CLO 1.0
Rating	AAA	AAA
Attach	33.80%	27.40%
Detach	100%	100%
Basel III	0.56%	2.40%
SSFA	1.60%	5.70%
Spread	1.45%	1.50%
Basel III ROC	259%	63%
SSFA ROC	91%	26%

Source: Citi Research

High return on bank capital


Figure 12 shows our estimate of the capital that is required in the standardized Basel approach (Basel III, based on ratings) and in the rule put forward by the joint US agencies (SSFA). Because of the Dodd-Frank Act, banks cannot use external ratings to assess capital charges for structured assets. The new rule is based on tranche subordination and quality of underlying collateral. (See [US Bank Capital Rule on Structured Credit](#) for details). CLO 1.0, being considered a resecuritization, has a higher weight for the same rating under both systems. The sample illustration shows that return on capital (ROC) regulatory capital on senior tranches still remains attractive for the US bank SSFA approach, but reduced versus Basel III.

US banks will get a much higher return on regulatory capital for investing in CLO 2.0 bonds. This leads to the conclusion that where possible, banks may decide to roll into bonds that are not penalized by the agencies' resecuritization haircut. Conversely, investors who do not find such a regulatory disincentive such as funds may well prefer the wider spread, discount prices and greater choice in the CLO 1.0 universe.

Euro CLO Mezz – Much to Hope


Defaults rising, but...

Figure 13. Trailing 12M speculative grade default rate, and percentage of ELLI universe rated CCC/CC




Source: S&P LCD

Figure 14. Distribution of debt maturities



Source: S&P LCD

Figure 15. Recoveries on European corporate first-lien debt. Universe size shown in parentheses.



Source: Citi Research

Standard and Poor's latest European default study³ of speculative grade companies may not surprise investors, but certainly will make loan and CLO investors take notice. As a counterpoint, though, an earlier but still recent recovery study on senior secured bank loans was a pleasant surprise with better data than initial rating agency assumptions. Let's start with the default. The economic and political uncertainty combined with a worsening growth and credit outlook is pushing LBO loans that are approaching maturity into a difficult position. The default rate of speculative-grade companies (rated 'BB+' or below) rose to 5.3% at the end of the second quarter, from 4.7% at the end of March 2012. Most of the recent defaulters were LBO, with several having defaulted previously. Further, the agency anticipates that the trailing 12-month default rate will edge up further over the next 12 months to reach 6.3% (or more) by the end of June 2013. Quite apart from the risk of the overall economic environment worsening more than their base case, there is a sizeable amount of debt coming due in the next two years (Figure 14). Issuance isn't helping to relieve the maturity wall either. In loan space, 2012 issuance is falling well short of 2011; the first nine months of 2012 have seen €20.4 billion issued, which is 45% lower than the year-ago period. HY bond issuance till Sep 28 2012 was EUR 27bn compared to EUR 34bn for the same period last year.

..recoveries surprise positively

Recoveries, on the other hand, have been good. Standard and Poor's found⁴ that mean nominal recoveries on European first-lien secured debt instruments that defaulted between 2003 and 2010 was 76%, which compares favorably with the US. However, the nominal European recovery rate includes a high volume (65%) of interim recoveries, generally debt exchanges, which could change with time. The smaller universe of credits for which ultimate recoveries are available (that is, the value of the settlement a lender receives by holding an instrument throughout its emergence from default) shows a lower, but still attractive, median recovery rate of 67% (Figure 15). Not only are these numbers higher than the agency assumptions for many European regimes when a CLO was created, the data also shows that recoveries for France and Spain are as good as, or better than, recoveries for the UK, despite the latter having a secured creditor-friendly legislation.

Trading prices can also provide additional insight even though, as the agency states, the secondary market for distressed debt is illiquid overall and there is some skepticism over whether or not debt is being written down to a sustainable level during restructurings. If we compare the restructurings where senior debt was simply converted into new instruments at par without additional equity given to the original investors, the mean and median recovery rates of the observed debt exchanges are 94% and 100%, respectively. However, the trading prices indicate a mean of 65% and a median of 80% (Figure 15). Where the exchange resulted in the investor receiving equity and loan, the trading value for just the loans is lower.

For CLO mezz, the mean default and recovery rates should still lead to a good outcome for an average-quality European deal, especially in light of the higher yields available in the European market, relative to the US. We consider the relative value proposition in greater detail below.


³ *European Corporate Defaults Are On The Rise As Eurozone Stresses Continue*, Standard and Poor's, 25 Sep 2012

⁴ *Europe's Senior Loan Market Delivers A Strong Recovery Performance Over Its First Cycle*. Standard and Poor's, 30 Apr 2012

Do Turbos Matter for Euro BBBs?

Relative value despite rally

Figure 16. Current subordination (x-axis) and spread, bps, for Euro and US CLO 1.0



Source: Citi Research

In a headline driven world, it is not surprising that the general rally in risk-assets, especially after statements by the ECB President to do all that is necessary to preserve the Euro, should benefit European CLOs. Mezz bonds have rallied as the Data Appendix in this report shows, but even now, the gap (Figure 16) between European and US CLOs should tempt some investors at least. Not only are spreads wider for European deals, but subordination level differences between the two CLO types are still intact after the credit cycle (because of lower recovery assumptions and lower diversification, Euro deals started life with higher subordination). Last year saw the spread discrepancy between the two CLOs initially decline at the beginning of the year with the entry of more relative-value investors, especially from the US. That momentum then declined, as investors chose to dig deeper into the US CLO capital stack to meet their yield requirements, but with signs of progress among European policymakers, the spread differential has narrowed a little. We predicted as such in our July [Global Structured Credit Strategy](#). Investors should be aware of this marginal investor dynamic as they put money to work in this market.

Figure 17. Sample universe of Euro CLO double- and triple-B tranches


	Turbo	Non Turbo
Sample Size	41	63
Attachment, median %	9.30	9.00
Attachment, std dev %	3.70	3.60
Interest diversion cushion, median %	-0.51	0.03
BB OC cushion, median %	2.57	2.72
BBB OC cushion, median %	5.72	6.00

Source: Citi Research, Intex

Turbo good for double-B, not bad for triple-B

That investors prefer double-Bs where excess interest pays down double-B debt to those that do not is not surprising. The relative attraction gets stronger when the tranches are close to failing their trigger and would then divert interest under their terms (a 'turbo-BB') as opposed where cash is diverted whenever it is available (a 'fast-pay'). Investors also say they prefer triple-Bs in deals that do not have turbo-BBs because such deals, in theory, trap interest in a credit deterioration which could be used to pay down more senior bonds. We think the value of this benefit is marginal, and if investors can pick up triple-B bonds that are cheap only because of this feature, they should do so.

Figure 18. Percentage of Euro CLO sample universe having principal loss versus assumed annual default rate (senior and mezz loan recovery at 60% and 20%)



Source: Citi Research, Intex

To test the hypothesis we selected a set of double- and triple-B tranches from the Euro CLO universe that did have the turbo feature, and others that did not. In addition to the original rating, we tried to keep the distribution of subordination below the samples similar to prevent one group performing better than the other under stress cases because of different attachment levels. The statistics for the two samples are shown in Figure 17. We subjected the collateral in each CLO to different default stresses (keeping the recovery and prepayment levels the same) to determine the rate at which tranches would lose principal or have interest shortfalls.

The results in Figure 18 show that triple-Bs, with or without turbos, are resilient well beyond the default and recovery assumptions that are forecast in the European markets (and only a small part of the double-B universe shows losses). Triple-Bs from turbo deals do a little worse but only under very high default rates. Double-Bs with turbos do slightly better as one would expect under moderate default rates but seem to do a little worse under much higher default rates, possibly for a slightly lower cushion in our sample (Figure 17). Overall, we feel that the presence of the turbo causes underperformance only at very high default rates and, unless investors consider this as their base case, they should use other considerations to select their bonds.

Appendix


Cash Flow CDO Market

Figure 19. Secondary Cash Flow CDO Spreads/Prices

Collateral Type	AAA	AA	A	BBB	BB
US HY CLO 1.0 (Spreads) – 1-Oct-12	145	230	400	600	775
US HY CLO 1.0 (Prices) – 1-Oct-12	Mid 90s – High 90s	Low 90s – Mid 90s	Low 70s – High 80s	Mid 70s – Low 80s	High 70s – Mid 80s
US HY CLO 2.0 (Spreads) – 1-Oct-12	145	230	355	540	740
US HY CLO 2.0 (Prices) – 1-Oct-12	High 90s – Par	High 90s – Par	Low 90s – High 90s	Mid 80s – High 80s	Mid 70s – Mid 80s
Euro HY CLO (Spreads) – 1-Oct-12	190	450	650	1150	1600
Euro HY CLO (Prices) – 1-Oct-12	Mid 90s – High 90s	Low 80s – Mid 80s	Low 70s – High 70s	Mid 50s – Mid 60s	Mid 50s – Mid 60s


Source: Citi Research

Figure 20. US CLO Tranche Spreads




Source: Citi Research

Figure 21. European CLO Tranche Spreads




Source: Citi Research

Figure 22. US CLO Tranche Prices



Source: Citi Research


Figure 23. European CLO Tranche Prices



Source: Citi Research


CLO Collateral

Figure 24. Avg First and Second-Lien Secondary Spreads to Maturity




Source: S&P

Figure 25. Weighted Average Bid




Source: S&P

Figure 26. US Lagging 12mo. Default Rate by Principal and # of Issuers




Source: S&P

Figure 27. US Quarterly Repayment Rate and Repayment Amount




Source: S&P

Figure 28. Collateral/Tranche Arbitrage (US Deals)




Source: Citi Research

Figure 29. Collateral/Tranche Arbitrage (EUR Deals)




Source: Citi Research

Figure 30. US Loan Distribution by Year of Maturity



Source: S&P


Figure 31. US Institutional Loans Launched to Market (Rolling 30-Days)



Source: S&P

Securitized Products Issuance


Figure 32. Year-to-Date CDO Issuance and Securitization Market Historical Issuance (\$bn)



Source: Bloomberg, Citi Research


Securitized and Non-securitized Products Returns

Figure 33. Simple Yield



Source: Citi Research

Figure 34. Total Returns, YTD 2012



Source: Citi Research

Appendix A-1

Analyst Certification

The research analyst(s) primarily responsible for the preparation and content of this research report are named in bold text in the author block at the front of the product except for those sections where an analyst's name appears in bold alongside content which is attributable to that analyst. Each of these analyst(s) certify, with respect to the section(s) of the report for which they are responsible, that the views expressed therein accurately reflect their personal views about each issuer and security referenced and were prepared in an independent manner, including with respect to Citigroup Global Markets Inc and its affiliates. No part of the research analyst's compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) expressed by that research analyst in this report.

IMPORTANT DISCLOSURES

Analysts' compensation is determined based upon activities and services intended to benefit the investor clients of Citigroup Global Markets Inc. and its affiliates ("the Firm"). Like all Firm employees, analysts receive compensation that is impacted by overall firm profitability which includes investment banking revenues.

For important disclosures (including copies of historical disclosures) regarding the companies that are the subject of this Citi Research product ("the Product"), please contact Citi Research, 388 Greenwich Street, 28th Floor, New York, NY, 10013, Attention: Legal/Compliance [E6WYB6412478]. In addition, the same important disclosures, with the exception of the Valuation and Risk assessments and historical disclosures, are contained on the Firm's disclosure website at https://www.citivelocity.com/cvr/eppublic/citi_research_disclosures. Valuation and Risk assessments can be found in the text of the most recent research note/report regarding the subject company. Historical disclosures (for up to the past three years) will be provided upon request.

NON-US RESEARCH ANALYST DISCLOSURES

Non-US research analysts who have prepared this report (i.e., all research analysts listed below other than those identified as employed by Citigroup Global Markets Inc.) are not registered/qualified as research analysts with FINRA. Such research analysts may not be associated persons of the member organization and therefore may not be subject to the NYSE Rule 472 and NASD Rule 2711 restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account. The legal entities employing the authors of this report are listed below:

Citigroup Global Markets Inc

Ratul Roy; Anindya Basu; Daniel Choi

OTHER DISCLOSURES

For securities recommended in the Product in which the Firm is not a market maker, the Firm is a liquidity provider in the issuers' financial instruments and may act as principal in connection with such transactions. The Firm is a regular issuer of traded financial instruments linked to securities that may have been recommended in the Product. The Firm regularly trades in the securities of the issuer(s) discussed in the Product. The Firm may engage in securities transactions in a manner inconsistent with the Product and, with respect to securities covered by the Product, will buy or sell from customers on a principal basis.

Securities recommended, offered, or sold by the Firm: (i) are not insured by the Federal Deposit Insurance Corporation; (ii) are not deposits or other obligations of any insured depository institution (including Citibank); and (iii) are subject to investment risks, including the possible loss of the principal amount invested. Although information has been obtained from and is based upon sources that the Firm believes to be reliable, we do not guarantee its accuracy and it may be incomplete and condensed. Note, however, that the Firm has taken all reasonable steps to determine the accuracy and completeness of the disclosures made in the Important Disclosures section of the Product. The Firm's research department has received assistance from the subject company(ies) referred to in this Product including, but not limited to, discussions with management of the subject company(ies). Firm policy prohibits research analysts from sending draft research to subject companies. However, it should be presumed that the author of the Product has had discussions with the subject company to ensure factual accuracy prior to publication. All opinions, projections and estimates constitute the judgment of the author as of the date of the Product and these, plus any other information contained in the Product, are subject to change without notice. Prices and availability of financial instruments also are subject to change without notice. Notwithstanding other departments within the Firm advising the companies discussed in this Product, information obtained in such role is not used in the preparation of the Product. Although Citi Research does not set a predetermined frequency for publication, if the Product is a fundamental research report, it is the intention of Citi Research to provide research coverage of the/those issuer(s) mentioned therein, including in response to news affecting this issuer, subject to applicable quiet periods and capacity constraints. The Product is for informational purposes only and is not intended as an offer or solicitation for the purchase or sale of a security. Any decision to purchase securities mentioned in the Product must take into account existing public information on such security or any registered prospectus.

Investing in non-U.S. securities, including ADRs, may entail certain risks. The securities of non-U.S. issuers may not be registered with, nor be subject to the reporting requirements of the U.S. Securities and Exchange Commission. There may be limited information available on foreign securities. Foreign companies are generally not subject to uniform audit and reporting standards, practices and requirements comparable to those in the U.S. Securities of some foreign companies may be less liquid and their prices more volatile than securities of comparable U.S. companies. In addition, exchange rate movements may have an adverse effect on the value of an investment in a foreign stock and its corresponding dividend payment for U.S. investors. Net dividends to ADR investors are estimated, using withholding tax rates conventions, deemed accurate, but investors are urged to consult their tax advisor for exact dividend computations. Investors who have received the Product from the Firm may be prohibited in certain states or other jurisdictions from purchasing securities mentioned in the Product from the Firm. Please ask your Financial Consultant for additional details. Citigroup Global Markets Inc. takes responsibility for the Product in the United States. Any orders by US investors resulting from the information contained in the Product may be placed only through Citigroup Global Markets Inc.

Important Disclosures for Morgan Stanley Smith Barney LLC Customers: Morgan Stanley & Co. LLC (Morgan Stanley) research reports may be available about the companies that are the subject of this Citi Research research report. Ask your Financial Advisor or use smithbarney.com to view any available Morgan Stanley research reports in addition to Citi Research research reports.

Important disclosure regarding the relationship between the companies that are the subject of this Citi Research research report and Morgan Stanley Smith Barney LLC and its affiliates are available at the Morgan Stanley Smith Barney disclosure website at www.morganstanleysmithbarney.com/researchdisclosures.

For Morgan Stanley and Citigroup Global Markets, Inc. specific disclosures, you may refer to www.morganstanley.com/researchdisclosures and https://www.citivelocity.com/cvr/eppublic/citi_research_disclosures.

This Citi Research research report has been reviewed and approved on behalf of Morgan Stanley Smith Barney LLC. This review and approval was conducted by the same person who reviewed this research report on behalf of Citi Research. This could create a conflict of interest.

The Citigroup legal entity that takes responsibility for the production of the Product is the legal entity which the first named author is employed by.

The Product is made available in **Australia** through Citi Global Markets Australia Pty Ltd. (ABN 64 003 114 832 and AFSL No. 240992), participant of the ASX Group and regulated by the Australian Securities & Investments Commission. Citigroup Centre, 2 Park Street, Sydney, NSW 2000. The Product is made available in Australia to Private Banking wholesale clients through Citigroup Pty Limited (ABN 88 004 325 080 and AFSL 238098). Citigroup Pty Limited provides all financial product advice to Australian Private Banking wholesale clients through bankers and relationship managers. If there is any doubt about the suitability of investments held in Citigroup Private Bank accounts, investors should contact the Citigroup Private Bank in Australia. Citigroup companies may compensate affiliates and their representatives for providing products and services to clients. The Product is made available in **Brazil** by Citigroup Global Markets Brasil - CCTVM SA, which is regulated by CVM - Comissão de Valores Mobiliários, BACEN - Brazilian Central Bank, APIMEC - Associação dos Analistas e Profissionais de Investimento do Mercado de Capitais and ANBID - Associação Nacional dos Bancos de Investimento. Av. Paulista, 1111 - 11º andar - CEP. 01311920 - São Paulo - SP. If the Product is being made available in certain provinces of **Canada** by Citigroup Global Markets (Canada) Inc. ("CGM Canada"), CGM Canada has approved the Product. Citigroup Place, 123 Front Street West, Suite 1100, Toronto, Ontario M5J 2M3. This product is available in **Chile** through Banchile Corredores de Bolsa S.A., an indirect subsidiary of Citigroup Inc., which is regulated by the Superintendencia de Valores y Seguros. Agustinas 975, piso 2, Santiago, Chile. The Product is made available in **France** by Citigroup Global Markets Limited, which is authorised and regulated by Financial Services Authority. 1-5 Rue Paul Cézanne, 8ème, Paris, France. The Product is distributed in **Germany** by Citigroup Global Markets Deutschland AG ("CGMD"), which is regulated by Bundesanstalt fuer Finanzdienstleistungsaufsicht (BaFin). CGMD, Reuterweg 16, 60323 Frankfurt am Main. Research which relates to "securities" (as defined in the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong)) is issued in **Hong Kong** by, or on behalf of, Citigroup Global Markets Asia Limited which takes full responsibility for its content. Citigroup Global Markets Asia Ltd. is regulated by Hong Kong Securities and Futures Commission. If the Research is made available through Citibank, N.A., Hong Kong Branch, for its clients in Citi Private Bank, it is made available by Citibank N.A., Citibank Tower, Citibank Plaza, 3 Garden Road, Hong Kong. Citibank N.A. is regulated by the Hong Kong Monetary Authority. Please contact your Private Banker in Citibank N.A., Hong Kong, Branch if you have any queries on or any matters arising from or in connection with this document. The Product is made available in **India** by Citigroup Global Markets India Private Limited, which is regulated by Securities and Exchange Board of India. Bakhtawar, Nariman Point, Mumbai 400-021. The Product is made available in **Indonesia** through PT Citigroup Securities Indonesia. 5/F, Citibank Tower, Bapindo Plaza, Jl. Jend. Sudirman Kav. 54-55, Jakarta 12190. Neither this Product nor any copy hereof may be distributed in Indonesia or to any Indonesian citizens wherever they are domiciled or to Indonesian residents except in compliance with applicable capital market laws and regulations. This Product is not an offer of securities in Indonesia. The securities referred to in this Product have not been registered with the Capital Market and Financial Institutions Supervisory Agency (BAPEPAM-LK) pursuant to relevant capital market laws and regulations, and may not be offered or sold within the territory of the Republic of Indonesia or to Indonesian citizens through a public offering or in circumstances which constitute an offer within the meaning of the Indonesian capital market laws and regulations. The Product is made available in **Israel** through Citibank NA, regulated by the Bank of Israel and the Israeli Securities Authority. Citibank, N.A. Platinum Building, 21 Ha'arba'ah St, Tel Aviv, Israel. The Product is made available in **Italy** by Citigroup Global Markets Limited, which is authorised and regulated by Financial Services Authority. Via dei Mercanti, 12, Milan, 20121, Italy. The Product is made available in **Japan** by Citigroup Global Markets Japan Inc. ("CGMJ"), which is regulated by Financial Services Agency, Securities and Exchange Surveillance Commission, Japan Securities Dealers Association, Tokyo Stock Exchange and Osaka Securities Exchange. Shin-Marunouchi Building, 1-5-1 Marunouchi, Chiyoda-ku, Tokyo 100-6520 Japan. If the Product was distributed by SMBC Nikko Securities Inc. it is being so distributed under license. In the event that an error is found in an CGMJ research report, a revised version will be posted on the Firm's Citi Velocity website. If you have questions regarding Citi Velocity, please call (81 3) 6270-3019 for help. The Product is made available in **Korea** by Citigroup Global Markets Korea Securities Ltd., which is regulated by the Financial Services Commission, the Financial Supervisory Service and the Korea Financial Investment Association (KOFIA). Citibank Building, 39 Da-dong, Jung-gu, Seoul 100-180, Korea. KOFIA makes available registration information of research analysts on its website. Please visit the following website if you wish to find KOFIA registration information on research analysts of Citigroup Global Markets Korea Securities Ltd. <http://dis.kofia.or.kr/fs/dis2/fundMgr/DISFundMgrAnalystPop.jsp?companyCd=A03030&pageDiv=02>. The Product is made available in Korea by Citibank Korea Inc., which is regulated by the Financial Services Commission and the Financial Supervisory Service. Address is Citibank Building, 39 Da-dong, Jung-gu, Seoul 100-180, Korea. The Product is made available in **Malaysia** by Citigroup Global Markets Malaysia Sdn Bhd (Company No. 460819-D) ("CGMM") to its clients and CGMM takes responsibility for its contents. CGMM is regulated by the Securities Commission of Malaysia. Please contact CGMM at Level 43 Menara Citibank, 165 Jalan Ampang, 50450 Kuala Lumpur, Malaysia in respect of any matters arising from, or in connection with, the Product. The Product is made available in **Mexico** by Acciones y Valores Banamex, S.A. De C. V., Casa de Bolsa, Integrante del Grupo Financiero Banamex ("Accival") which is a wholly owned subsidiary of Citigroup Inc. and is regulated by Comisión Nacional Bancaria y de Valores. Reforma 398, Col. Juárez, 06600 Mexico, D.F. In **New Zealand** the Product is made available to 'wholesale clients' only as defined by s5C(1) of the Financial Advisers Act 2008 ("FAA") through Citigroup Global Markets Australia Pty Ltd (ABN 64 003 114 832 and AFSL No. 240992), an overseas financial adviser as defined by the FAA, participant of the ASX Group and regulated by the Australian Securities & Investments Commission. Citigroup Centre, 2 Park Street, Sydney, NSW 2000. The Product is made available in **Pakistan** by Citibank N.A. Pakistan branch, which is regulated by the State Bank of Pakistan and Securities Exchange Commission, Pakistan. AWT Plaza, 1.1. Chundrigar Road, P.O. Box 4889, Karachi-74200. The Product is made available in the **Philippines** through Citicorp Financial Services and Insurance Brokerage Philippines, Inc., which is regulated by the Philippines Securities and Exchange Commission. 20th Floor Citibank Square Bldg. The Product is made available in the Philippines through Citibank NA Philippines branch, Citibank Tower, 8741 Paseo De Roxas, Makati City, Manila. Citibank NA Philippines NA is regulated by The Bangko Sentral ng Pilipinas. The Product is made available in **Poland** by Dom Maklerski Banku Handlowego SA an indirect subsidiary of Citigroup Inc., which is regulated by Komisja Nadzoru Finansowego. Dom Maklerski Banku Handlowego S.A. ul.Senatorska 16, 00-923 Warszawa. The Product is made available in the **Russian Federation** through ZAO Citibank, which is licensed to carry out banking activities in the Russian Federation in accordance with the general banking license issued by the Central Bank of the Russian Federation and brokerage activities in accordance with the license issued by the Federal Service for Financial Markets. Neither the Product nor any

information contained in the Product shall be considered as advertising the securities mentioned in this report within the territory of the Russian Federation or outside the Russian Federation. The Product does not constitute an appraisal within the meaning of the Federal Law of the Russian Federation of 29 July 1998 No. 135-FZ (as amended) On Appraisal Activities in the Russian Federation. 8-10 Gasheka Street, 125047 Moscow. The Product is made available in **Singapore** through Citigroup Global Markets Singapore Pte. Ltd. ("CGMSPL"), a capital markets services license holder, and regulated by Monetary Authority of Singapore. Please contact CGMSPL at 8 Marina View, 21st Floor Asia Square Tower 1, Singapore 018960, in respect of any matters arising from, or in connection with, the analysis of this document. This report is intended for recipients who are accredited, expert and institutional investors as defined under the Securities and Futures Act (Cap. 289). The Product is made available by The Citigroup Private Bank in Singapore through Citibank, N.A., Singapore Branch, a licensed bank in Singapore that is regulated by Monetary Authority of Singapore. Please contact your Private Banker in Citibank N.A., Singapore Branch if you have any queries on or any matters arising from or in connection with this document. This report is intended for recipients who are accredited, expert and institutional investors as defined under the Securities and Futures Act (Cap. 289). This report is distributed in Singapore by Citibank Singapore Ltd ("CSL") to selected Citigold/Citigold Private Clients. CSL provides no independent research or analysis of the substance or in preparation of this report. Please contact your Citigold/Citigold Private Client Relationship Manager in CSL if you have any queries on or any matters arising from or in connection with this report. This report is intended for recipients who are accredited investors as defined under the Securities and Futures Act (Cap. 289). Citigroup Global Markets (Pty) Ltd. is incorporated in the **Republic of South Africa** (company registration number 2000/025866/07) and its registered office is at 145 West Street, Sandton, 2196, Saxonwold. Citigroup Global Markets (Pty) Ltd. is regulated by JSE Securities Exchange South Africa, South African Reserve Bank and the Financial Services Board. The investments and services contained herein are not available to private customers in South Africa. The Product is made available in **Spain** by Citigroup Global Markets Limited, which is authorised and regulated by Financial Services Authority. 29 Jose Ortega Y Gasset, 4th Floor, Madrid, 28006, Spain. The Product is made available in the **Republic of China** through Citigroup Global Markets Taiwan Securities Company Ltd. ("CGMTS"), 14 and 15F, No. 1, Songzhi Road, Taipei 110, Taiwan and/or through Citibank Securities (Taiwan) Company Limited ("CSTL"), 14 and 15F, No. 1, Songzhi Road, Taipei 110, Taiwan, subject to the respective license scope of each entity and the applicable laws and regulations in the Republic of China. CGMTS and CSTL are both regulated by the Securities and Futures Bureau of the Financial Supervisory Commission of Taiwan, the Republic of China. No portion of the Product may be reproduced or quoted in the Republic of China by the press or any third parties [without the written authorization of CGMTS and CSTL]. If the Product covers securities which are not allowed to be offered or traded in the Republic of China, neither the Product nor any information contained in the Product shall be considered as advertising the securities or making recommendation of the securities in the Republic of China. The Product is for informational purposes only and is not intended as an offer or solicitation for the purchase or sale of a security or financial products. Any decision to purchase securities or financial products mentioned in the Product must take into account existing public information on such security or the financial products or any registered prospectus. The Product is made available in **Thailand** through Citicorp Securities (Thailand) Ltd., which is regulated by the Securities and Exchange Commission of Thailand. 18/F, 22/F and 29/F, 82 North Sathorn Road, Silom, Bangrak, Bangkok 10500, Thailand. The Product is made available in **Turkey** through Citibank AS which is regulated by Capital Markets Board. Tekfen Tower, Eski Buyukdere Caddesi # 209 Kat 2B, 23294 Levent, Istanbul, Turkey. In the **U.A.E.**, these materials (the "Materials") are communicated by Citigroup Global Markets Limited, DIFC branch ("CGML"), an entity registered in the Dubai International Financial Center ("DIFC") and licensed and regulated by the Dubai Financial Services Authority ("DFS") to Professional Clients and Market Counterparties only and should not be relied upon or distributed to Retail Clients. A distribution of the different Citi Research ratings distribution, in percentage terms for Investments in each sector covered is made available on request. Financial products and/or services to which the Materials relate will only be made available to Professional Clients and Market Counterparties. The Product is made available in **United Kingdom** by Citigroup Global Markets Limited, which is authorised and regulated by Financial Services Authority. This material may relate to investments or services of a person outside of the UK or to other matters which are not regulated by the FSA and further details as to where this may be the case are available upon request in respect of this material. Citigroup Centre, Canada Square, Canary Wharf, London, E14 5LB. The Product is made available in **United States** by Citigroup Global Markets Inc, which is a member of FINRA and registered with the US Securities and Exchange Commission. 388 Greenwich Street, New York, NY 10013. Unless specified to the contrary, within EU Member States, the Product is made available by Citigroup Global Markets Limited, which is regulated by Financial Services Authority.

Pursuant to Comissão de Valores Mobiliários Rule 483, Citi is required to disclose whether a Citi related company or business has a commercial relationship with the subject company. Considering that Citi operates multiple businesses in more than 100 countries around the world, it is likely that Citi has a commercial relationship with the subject company.

Many European regulators require that a firm must establish, implement and make available a policy for managing conflicts of interest arising as a result of publication or distribution of investment research. The policy applicable to Citi Research's Products can be found at https://www.citivelocity.com/cvr/eppublic/citi_research_disclosures.

Compensation of equity research analysts is determined by equity research management and Citigroup's senior management and is not linked to specific transactions or recommendations.

The Product may have been distributed simultaneously, in multiple formats, to the Firm's worldwide institutional and retail customers. The Product is not to be construed as providing investment services in any jurisdiction where the provision of such services would not be permitted.

Subject to the nature and contents of the Product, the investments described therein are subject to fluctuations in price and/or value and investors may get back less than originally invested. Certain high-volatility investments can be subject to sudden and large falls in value that could equal or exceed the amount invested. Certain investments contained in the Product may have tax implications for private customers whereby levels and basis of taxation may be subject to change. If in doubt, investors should seek advice from a tax adviser. The Product does not purport to identify the nature of the specific market or other risks associated with a particular transaction. Advice in the Product is general and should not be construed as personal advice given it has been prepared without taking account of the objectives, financial situation or needs of any particular investor. Accordingly, investors should, before acting on the advice, consider the appropriateness of the advice, having regard to their objectives, financial situation and needs. Prior to acquiring any financial product, it is the client's responsibility to obtain the relevant offer document for the product and consider it before making a decision as to whether to purchase the product. With the exception of our product that is made available only to Qualified Institutional Buyers (QIBs) and other product that is made available through other distribution channels only to certain categories of clients to satisfy legal or regulatory requirements, Citi Research concurrently disseminates its research via proprietary and non-proprietary electronic distribution platforms. Periodically, individual Citi Research analysts may also opt to circulate research posted on such platforms to one or more clients by email. Such email distribution is discretionary and is done only after the research has been disseminated via the aforementioned distribution channels. Citi Research simultaneously distributes product that is limited to QIBs only through email distribution.

The level and types of services provided by Citi Research analysts to clients may vary depending on various factors such as the client's individual

preferences as to the frequency and manner of receiving communications from analysts, the client's risk profile and investment focus and perspective (e.g. market-wide, sector specific, long term, short-term etc.), the size and scope of the overall client relationship with Citi and legal and regulatory constraints. Citi Research product may source data from dataCentral. dataCentral is a Citi Research proprietary database, which includes Citi estimates, data from company reports and feeds from Reuters and Datastream.

© 2012 Citigroup Global Markets Inc. Citi Research is a division of Citigroup Global Markets Inc. Citi and Citi with Arc Design are trademarks and service marks of Citigroup Inc. and its affiliates and are used and registered throughout the world. All rights reserved. Any unauthorized use, duplication, redistribution or disclosure of this report (the "Product"), including, but not limited to, redistribution of the Product by electronic mail, posting of the Product on a website or page, and/or providing to a third party a link to the Product, is prohibited by law and will result in prosecution. The information contained in the Product is intended solely for the recipient and may not be further distributed by the recipient to any third party. Where included in this report, MSCI sourced information is the exclusive property of Morgan Stanley Capital International Inc. (MSCI). Without prior written permission of MSCI, this information and any other MSCI intellectual property may not be reproduced, disseminated or used to create any financial products, including any indices. This information is provided on an "as is" basis. The user assumes the entire risk of any use made of this information. MSCI, its affiliates and any third party involved in, or related to, computing or compiling the information hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability or fitness for a particular purpose with respect to any of this information. Without limiting any of the foregoing, in no event shall MSCI, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind. MSCI, Morgan Stanley Capital International and the MSCI indexes are services marks of MSCI and its affiliates. The Firm accepts no liability whatsoever for the actions of third parties. The Product may provide the addresses of, or contain hyperlinks to, websites. Except to the extent to which the Product refers to website material of the Firm, the Firm has not reviewed the linked site. Equally, except to the extent to which the Product refers to website material of the Firm, the Firm takes no responsibility for, and makes no representations or warranties whatsoever as to, the data and information contained therein. Such address or hyperlink (including addresses or hyperlinks to website material of the Firm) is provided solely for your convenience and information and the content of the linked site does not in anyway form part of this document. Accessing such website or following such link through the Product or the website of the Firm shall be at your own risk and the Firm shall have no liability arising out of, or in connection with, any such referenced website.

ADDITIONAL INFORMATION IS AVAILABLE UPON REQUEST
